Dermatology Surgery and Laser Center, White Plains, NY 10604, USA.
Dermatol Surg. 2011 May;37(5):644-50. doi: 10.1111/j.1524-4725.2010.01863.x. Epub 2011 Jan 31.
An 18-month persistence study reported nasolabial fold (NLF) improvements using a small gel-particle hyaluronic acid (SGP-HA) dermal filler lasted up to 18 months after one retreatment.
[corrected] To evaluate the efficacy and persistence of SGP-HA for the correction of NLFs for up to 36 months.
METHODS & MATERIALS: Subjects completing the 18-month persistence study were permitted to enroll in an 18-month extension trial. Most required second retreatments to achieve optimal correction of their NLFs. Subjects were followed for up to 36 months after their initial treatment. The primary efficacy measure was a 1-point improvement from baseline Wrinkle Severity Rating Scale (WSRS) score as determined by a blinded evaluator at different time points.
The study enrolled 52 subjects. Forty subjects required a second retreatment for optimum NLF correction. Mean retreatment volume was less than 50% of the initial treatment volume. Twenty-six subjects completed the study. Blinded assessments revealed that 94% to 100% of subjects maintained WSRS scores of 1 point or more higher than baseline throughout the study.
Participants in the 18-month extension of an 18-month SGP-HA persistence study continued to demonstrate improvement of NLFs up to 36 months after a second retreatment. The mean volume of SGP-HA required for optimum NLF correction decreased substantially with each retreatment. Subjects reported no treatment-related adverse events after the second retreatment.
一项为期 18 个月的持续性研究报告称,使用小颗粒凝胶型透明质酸(SGP-HA)真皮填充剂治疗鼻唇沟(NLF),在一次追加治疗后长达 18 个月可保持改善效果。
评估 SGP-HA 治疗 NLF 的疗效和持久性,最长可达 36 个月。
完成 18 个月持续性研究的受试者可参加为期 18 个月的扩展试验。大多数患者需要进行第二次追加治疗,以实现 NLF 的最佳矫正。受试者在初始治疗后最多可随访 36 个月。主要疗效指标为盲法评估员在不同时间点确定的皱纹严重程度评分量表(WSRS)基线评分改善 1 分。
该研究纳入了 52 名受试者。40 名受试者需要进行第二次追加治疗以实现 NLF 的最佳矫正。平均追加治疗体积小于初始治疗体积的 50%。26 名受试者完成了研究。盲法评估显示,94%至 100%的受试者在整个研究过程中维持的 WSRS 评分均比基线高 1 分或以上。
在为期 18 个月的 SGP-HA 持续性研究的 18 个月扩展期中,参与者在第二次追加治疗后长达 36 个月持续改善 NLF。每次追加治疗时,用于最佳 NLF 矫正的 SGP-HA 平均体积显著减少。第二次追加治疗后,受试者报告无治疗相关不良事件。